corporate articles

RevolKa Reimagines Antibody Engineering with “RevoAb®”

Corporate Website Renewal Notice

RevolKa announces the closing of ￥250 million series A extension funding to accelerate Drug-Discovery programs

RevolKa has been selected as a member of the Google for Startups Cloud Program.